State Street Corp Cuts Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK)

State Street Corp lessened its position in OPKO Health, Inc. (NASDAQ:OPK) by 8.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,715,510 shares of the biotechnology company’s stock after selling 832,705 shares during the quarter. State Street Corp owned about 1.28% of OPKO Health worth $12,986,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. CIBC Asset Management Inc raised its holdings in OPKO Health by 79.1% in the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 8,978 shares during the last quarter. Hollencrest Capital Management lifted its position in OPKO Health by 14.0% during the second quarter. Hollencrest Capital Management now owns 90,000 shares of the biotechnology company’s stock worth $112,000 after buying an additional 11,020 shares in the last quarter. FMR LLC grew its holdings in OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 11,089 shares in the last quarter. PFG Investments LLC raised its holdings in shares of OPKO Health by 2.5% during the 2nd quarter. PFG Investments LLC now owns 960,965 shares of the biotechnology company’s stock worth $1,201,000 after acquiring an additional 23,700 shares during the period. Finally, Private Advisor Group LLC boosted its holdings in OPKO Health by 242.7% in the 3rd quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 25,000 shares during the last quarter. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

OPKO Health Price Performance

OPK opened at $1.51 on Thursday. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of -7.95 and a beta of 1.62. The stock’s 50-day moving average price is $1.54 and its 200 day moving average price is $1.48. OPKO Health, Inc. has a 12-month low of $0.85 and a 12-month high of $1.76.

Wall Street Analysts Forecast Growth

OPK has been the topic of a number of recent analyst reports. Piper Sandler reiterated an “overweight” rating and issued a $3.00 price objective on shares of OPKO Health in a report on Tuesday, September 17th. StockNews.com cut shares of OPKO Health from a “hold” rating to a “sell” rating in a research report on Thursday. Barrington Research reiterated an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research report on Friday, November 8th. Finally, HC Wainwright restated a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a report on Thursday, September 26th.

Insider Activity

In related news, CEO Phillip Md Et Al Frost bought 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The stock was purchased at an average cost of $1.62 per share, for a total transaction of $162,000.00. Following the completion of the acquisition, the chief executive officer now owns 211,612,405 shares in the company, valued at approximately $342,812,096.10. This trade represents a 0.05 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders acquired 1,304,255 shares of company stock valued at $2,024,605. 47.26% of the stock is currently owned by company insiders.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.